Why Arena Pharmaceuticals Stock Slimmed Down in March

Why Arena Pharmaceuticals Stock Slimmed Down in March


Interestingly enough, though, the biotech's stock slumped last month without a discernible material or newsworthy event. In fact, the drugmaker's shares were actually up by double digits early in March following an upbeat fourth-quarter earnings release and pipeline update.



from Biotech News